title: [Moxifloxacin in the treatment of chronic bronchitis--clinical evaluation and assessment by patients].
abstract: METHODS
  The aim of this trial conducted in the offices of pneumologists was to evaluate the clinical success of a 5-day course of oral moxifloxacin administered once daily at a dose of 400 mg in 328 patients with acute exacerbation of chronic bronchitis (Anthonisen type 1). In this non-comparative study, the results of treatment were assessed not merely on the basis of the clinical parameters, but also, for the first time, by the surrogate marker of patient satisfaction and the improvement in cough, dyspnea, chest pain and sputum, the severity of which was scored daily by the patient himself.
  
  
  RESULTS
  Cough, chest pain and the purulence of the sputum improved rapidly within the first five days of treatment. At least 90% of the patients reported their satisfaction with the antibiotic. The clinical success rate (cure and improvement) for all the patients involved (ITT analysis) was 90.5%. The most common side effect was diarrhea, while the other side effects showed no specific pattern.
authors.affiliation: Innere Abteilung II, Kreiskrankenhaus Lüdenscheid.
authors.forename: J
authors.initials: J
authors.lastname: Lorenz
authors.forename: W
authors.initials: W
authors.lastname: Busch
authors.forename: I M
authors.initials: IM
authors.lastname: Thate-Waschke
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001372:Aza Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D029481:Bronchitis, Chronic / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D003371:Cough / Q000209:etiology; D005260:Female; D024841:Fluoroquinolones; D005541:Forced Expiratory Volume; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077266:Moxifloxacin; D017060:Patient Satisfaction; D011788:Quality of Life; D011804:Quinolines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin